Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Narrative Review

Probiotics: A gut response to the COVID-19 pandemic but what does the evidence show?

Sandrayee Brahma a, Amruta Naik b, Ronan Lordan c, d, e, *

a Dr Harvey’s, Atlantic Highlands, NJ, USA
b Children’s Hospital of Philadelphia, Philadelphia, PA, USA
c Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
d Department of Systems Pharmacology and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
e Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first identified in the city of Wuhan, China, in November 2019 is responsible for the coronavirus disease 2019 (COVID-19) that has resulted in almost 6.5 million deaths and over 600 million confirmed cases across the globe [1]. While vaccines have lowered the risk of death, hospitalization, and to some extent infection, the hunt for additional prophylactics and therapeutics is still ongoing. Among these, probiotics were deemed of interest due to their potential immunomodulatory and anti-inflammatory effects, as well as their putative protective effects against viral diseases [2,3]. Probiotics are generally defined as “live microorganisms that, when administered in adequate amounts, confer a health benefit to the host” [4], although it should be noted that multiple definitions exist that are interpreted in various ways [5]. These discrepancies have contributed to differing regulation regarding probiotics in Europe and North America [6]. Despite these regulatory issues, interest surrounding probiotics and their potential benefits have not waned and probiotics are among the main products intentionally consumed by humans to beneficially affect the gut microbiome to improve health [7,8]. Research has continued to grow over the last decade with a fivefold increase in the number of publications published between 2010 and 2021 in PubMed alone relating to “probiotics” [9]. Among the areas of research being investigated, probiotics administration and their potential effects on the gut microbiome and subsequent health and protection against respiratory infections has been explored.

The human microbiome is the sum of all microfloras present in our tissues and fluids. The microbiome is composed of diverse bacteria (bacteriome), fungi (mycobiome), protozoa, and even viruses (virome). The human gut microbiome alone accounts for a collection of between 100 million to 100 trillion commensal...
Coronaviruses that affect humans are generally associated with respiratory infections, and occasionally the gastrointestinal tract [24]. Angiotensin-converting enzyme 2 (ACE2) is the cellular gateway of the SARS-CoV-2 spike protein [24]. A recent study by Xu et al. conducted retrospective analysis of bulk tissue RNA of the digestive tract organs and lungs from a public database and observed that the digestive tract had higher ACE2 expression levels compared to the lung, and the expression of ACE2 in the lung increased with age [25]. In the gut, SARS-CoV-2 targets both the proximal and distal enterocytes [26] and there is evidence that SARS-CoV-2 can be prevalent in the mucous membranes of the oesophagus, stomach, and tissues of the small and large intestines [27,28]. Therefore, it is not surprising that SARS-CoV-2 infection induces gastrointestinal symptoms in adults and children [29,30]. Factors that affect gut health may also have negative consequences for a patient’s nutritional status, which is now under investigation in relation to COVID-19 [31]. Indeed, many host factors can affect the microbiome including one’s health, diet, exercise, and lifestyle choices [32,33].

SARS-CoV-2 enters the host via the respiratory system, which may implicate the lung microbiome in the etiology of COVID-19 [34]. Indeed, this has led researchers to question the role of the gut-lung axis and how its modulation may affect COVID-19 outcomes [35]. The aim of this review is to provide an update and cast a critical eye on the current state of research regarding the gut-lung axis in relation to the microbiome, probiotics, nutritional status, and their interactions in relation to COVID-19. Additionally, we discuss the current state of clinical trials investigating the modulation of the gut and lung microbiome via probiotics administration in humans. We highlight the need for a greater understanding of how probiotics affect the gut microbiome and immune function in response to viral infections.

2. The gut-lung microbiome axis and COVID-19

Attenuating the gut and/or lung microbiome is a strategy that has been previously explored for viral infections. Research has shown that lactic acid bacteria (LAB) can be used to treat oral [36], vaginal [37,38], and gastrointestinal infections [39] in animal and human studies. Probiotics have also been shown to be effective against respiratory infections. Administration of Lactobacillus gasseri to mice reduced respiratory syncytial virus (RSV) viral titers, increased interferon I and II, and decreased cytokines in the lung [40]. The latter findings are in agreement with other studies that suggest nasal and oral administration of LAB may exert anti-inflammatory effects against RSV in mice [41,42].

Considering nasal and oral routes of probiotic administration may be beneficial against viral infection in vivo, some speculate a mechanistic role for the gut-lung axis in amelioration of respiratory viral infections. As alluded to, microbial metabolites can affect host health on a system level by producing vital metabolic byproducts from dietary components [43,44]. One of the most studied of these microbiome-derived metabolites for their potential human health benefits are short chain fatty acids (SCFA), such as acetic acid, butyric acid, and propionic acid. SCFA act as the main sources of energy for intestinal epithelial cells and thereby help to strengthen the immune system through Toll-like receptor (TLR) expression, differentiation of T cells including CD4+ T cells, and antibody expression [45]. Butyrate has been touted as a potential therapy to prevent the development of ARDS and the cytokine storm via immune response modulation and potentially proresolving factors [45]. In accordance, depletion of butyrate-producing microbiota may also be linked to a potential increased risk of COVID-19 in hypertonization patients via down regulating pathways integral to SARS-CoV-2 infection, upregulating antiviral and TLR related genes, and modulating Ace2 and Tmprss2 gene expression as demonstrated in a gut epithelium organoid model [46]. Although these findings have not been validated in human studies, there is evidence that the gut microbiome of COVID-19 patients have impaired capacity to produce SCFA, which persists into recovery and correlates with host immune responses [47]. Contrariwise, some in vitro evidence casts doubt on the benefits of SCFA in the prevention of SARS-CoV-2 infection in gut tissue [48]. Though promising, alteration of the gut microbiome to favor synthesis of SCFA requires further research.

Because alterations to the gut microbiome have been previously implicated in the outcomes of patients with viral infections [49–51], the scientific community speculates that there could be a strong link associated with the risk factors for COVID-19 driven by poor diet consisting of high saturated fat, high sugar, refined carbohydrates and lesser amounts of fibers, unsaturated fat, and polyphenols, leading to a dysbiosis in gut microbial community [52–54]. Dysbiosis is a mechanism whereby an imbalance of the microbiome occurs because of disruption of the microbiota homeostasis. Many factors including host genetics, diet, supplementation, stress, infection, and/or medical interventions (such as antibiotics) influence the microbial community at compositional and functional levels [55]. The gut microbiome affects pulmonary health through a crosstalk via the gut-lung axis [56–59]. Consequently, the role of the gut and lung microbiomes in SARS-CoV-2 infection susceptibility and COVID-19 severity and their modulation by probiotics are under investigation.

A systematic review of COVID-19 and the microbiome determined that the human fecal microbiomes were altered by COVID-19, which was characterized by a greater prevalence of opportunistic pathogens [34]. The presence of such pathogens is a concern due to the potential for further dysbiosis or nosocomial infections. These findings are important, because it is known that the commensal microbiota can modulate virus-specific adaptive immune responses. Several studies have shown that germ free mice or mice orally treated with antibiotics have impaired responses to systemic and respiratory infections [60–63]. Numerous mechanisms have been proposed for how the microbiome may prime the lungs to control respiratory infections including production of type I interferons (IFNs) [64–66] or modulation of adaptive immune responses via activation of CD4+ and CD8+ T cells [67].

3. Targeting the gut-lung microbiome axis and its clinical significance

The oropharynx and gastrointestinal tract are physiologically interlinked and share similar microbial compositions, albeit the lung microbiota has a significantly lower biomass than the gut microbiota whose diversity depends on the conditions in the entire respiratory tract [19,68]. There has been no shortage of studies demonstrating a link between lung health and the lung and gut microbiomes [19,68–71]. As discussed, the microbiota and their metabolites play an important role in the development of the immune system both locally and systemically. However, alterations to the gut microbiome by diet, medical interventions or disease has
been shown to alter immune responses to the respiratory system [72]. It is irrefutable that an individual’s diet and lifestyle contributes to a person’s risk of non-communicable diseases [73–75]. The same is true of how nutritional status contributes to one’s susceptibility to acute illnesses such as infectious diseases [76,77] as nutritional status is interlinked with immune function [78]. Indeed, deficiency of a single nutrient may weaken immune function [79]. There is already emerging evidence that a patient’s nutritional status is an important factor in COVID-19 [31,80–82]. A bidirectional relationship exists, whereby the gut microbiome affects nutritional status and vice versa [83,84], which likely affects COVID-19 risk [85]. These links are mediated by metabolites generated by gut microbiota in response to factors such as nutrition or drug intake. These metabolites can act locally and systemically to affect multiple systems, including the respiratory system [72]. Therefore, the maintenance of the gut microbiome prior to, during, and past COVID-19 through appropriate dietary and therapeutic measures is critical for positive patient outcomes and recovery [51,86]. As a consequence, several guidelines have been devised to promote COVID-19 patient recovery [87].

In COVID-19 patients, several studies show that the lung [23,88,89] and gut microbiota [30,56] composition is altered versus non-COVID-19 patients, which in the case of the gut at least seems to stratify according to disease severity [51]. Depletion of the gut microbiome is associated with immune modulation and can remain low for up to 30 days [51]. In some cases, gut dysbiosis can persist six-months post infection [90]. This is important as gut dysbiosis has been linked to dysbiosis in the lung microbiome, both in animal studies and in humans and may potentially have long-term gut and lung health implications [21,91–93]. A systematic review highlighted that the majority of existing studies have determined that both the upper and lower respiratory tract microbiome is altered by COVID-19. These alterations are characterized by a greater prevalence of opportunistic pathogens [22]. Therefore, it is no surprise that studies have shown that respiratory tract co-infections are common among COVID-19 patients [94–96]. In the upper respiratory tract, it has been reported that pathogenic Candida albicans, human alpha-herpesvirus, RSV, and influenza were in abundance [94]. Other studies have also confirmed the presence of RSV and influenza A/B, along with rhinoviruses and enteroviruses in abundance [95]. These findings also highlight that fungal dysbiosis is prevalent in COVID-19 patients. Indeed, this is important considering the emerging role of the mycobiome and fungal dysbiosis as a contributor to immune dysregulation in infectious diseases [97] immune system development [98].

Host transcriptomics show that severe COVID-19 patients that develop secondary bacterial infections such as ventilator-associated pneumonia (VAP) may have respiratory microbiome disturbances and impaired antibacterial immune defenses before infection onset. Which begs the question whether point-of-care prognostic tools may be developed to predict VAP prior to occurrence [99]. Indeed, one study has shown sampling on arrival to either the Emergency Department or COVID-19 unit of one hospital was predictive of the need for respiratory support. An oropharyngeal microbiome denoted by a reduced abundance of Prevotella salivae and metabolic pathways associated with mycolic acid and liposaccharide biosynthesis appeared to be of prognostic value [100]. Severe COVID-19 patients also experience acute respiratory distress syndrome (ARDS) [101], which induces the production of pro-inflammatory cytokines such as TNF-a, IL-10, IL-7, IL-2, MCP1 and others that can cause extensive organ damage [102]. Studies prior to the pandemic have shown that certain gut microbiome colonization patterns are associated with these same inflammatory markers [103] indicating a potential role of the gut microbiome in ARDS.

Gut dysbiosis appears to be a common clinical feature of COVID-19 patients [104] and has been correlated with IL-18 detection in fecal material, which is unique to COVID-19 patients [105]. COVID-19 patients also have 3-fold increase in fungal diversity and pathogens from the genus Aspergillus in the gut. More severe COVID-19 symptoms were associated with patients who had high abundance of more than two Aspergillus pathogens. Despite nasopharyngeal clearance of SARS-CoV-2 these fungi were found to be present in the feces, hinting to persistent colonization of fungal pathogens and a potential threat to the host in the longer term [106]. The same study found that there was an increase in the opportunistic pathogens over beneficial commensals, which is in accordance with previous studies [34]. It is also important to recognize that pre-existing conditions play a role in COVID-19 outcomes [24]. Inflammatory diseases such as inflammatory bowel disease (IBD), colon cancer, and even diseases such as rheumatoid arthritis and liver cirrhosis have been associated with microbial translocation along the oral–gut axis [107]. This implies that microbes from either the gut or lung may have the capacity to translocate to each other or different organs that may affect COVID-19 outcomes and may have long-term health implications.

4. Investigation of probiotics for COVID-19 mitigation in clinical trials

The popularity of probiotics has increased over the last two decades, and they have been investigated during the pandemic due to the putative health benefits [108,109]. Several authors have speculated that probiotics/probiotics may prevent and/or treat COVID-19 [16,86,110–115] via modulation of the gut microbiota and the gut-lung axis. Previous studies have shown a beneficial effect of probiotic intake against some respiratory infections [116–118], potentially through immunomodulatory effects [2,3] and anti-inflammatory effects [119,120]. Probiotics may even enhance the antibody response generated by immunization [121–124]. To date, there have been few clinical trials published (Table 1) investigating the potential therapeutic role of probiotics in relation to COVID-19. However, there are over 25 registered clinical trials that aim to investigate the biological and therapeutic roles of probiotic administration on COVID-19 management (Table 2). Various individual species and formulations of probiotics are thought to affect immune function [120,125], which may also affect COVID-19 outcomes, which is reflected in the combinations of probiotics administered to patients in both Table 1 and in Table 2. In general, the majority of probiotics utilized consist of lactic acid bacteria (LAB) including Lactobacillus and Bifidobacterium. LAB have long been touted as potential immune modulators and as such are the obvious choice to investigate.

Of the limited published trials to date (Table 1), the main findings as a result of probiotic administration appears to be a more rapid improvement of symptoms, reduced fatigue, and potentially resolution of gastrointestinal issues. Gutiérrez-Castrellón, Gandara-Martí [126] observed more rapid recovery (p < 0.0001) and shortening of symptom duration following administration of a probiotic (n = 147; Lactiplantibacillus plantarum KABP022, KABP023, and KABP033, and Pedicoccus acidilactici KABP021) versus placebo (n = 146) in a 30-day intervention in a blinded, randomized, placebo-controlled trial. Zhang, Han [129] retrospectively analyzed the efficacy of a probiotic (Bifidobacterium, Lactobacillus, and Enterococcus - detailed breakdown unavailable) administered to 196 COVID-19 patients receiving standard of care (SOC) versus a matched cohort of patients receiving SOC alone (n = 179). They noted an improved time to clinical improvement (p < 0.022),
Table 1
Published studies investigating the administration of probiotics and their effects on SARS-CoV-2 transmission, infection, COVID-19, and related post sequelae.

| Reference | Country | Aim | Study Design | Outcomes | Strains |
|-----------|---------|-----|--------------|----------|---------|
| Gutiérrez-Castrellón, Gandara-Martí [126] (Preprint) Mexico | To assess the efficacy and safety of probiotics in symptomatic adult COVID-19 outpatients | Single center, quadruple blinded, randomized placebo-controlled trial Treatment: Probiotic formulation 30-day intervention | Placebo n = 146 Treatment n = 147 14-day intervention | Disease recovery (remission) was more rapid in the probiotics group (p < 0.0001) Shortening of symptom duration No hospitalizations/deaths occurred during the intervention No adverse events reported | Lactiplantibacillus plantarum(KABP022, KABP023, and KABP033), Pediococcus acidilactici(KABP021) |
| Rath, Jadhav [127] India | To assess the efficacy and safety of probiotics and a systemic enzyme complex in adults with fatigue induced by post sequelae of previously confirmed COVID-19 | Multicenter, double blinded, randomized placebo-controlled trial Treatment: Probiotic formulation and an enzyme supplement (containing serratopeptase, bromelain, amylase, lysozyme, peptidase, glucoamylase, catalase, papain, lactoferrin) 14-day intervention Placebo n = 100 Treatment n = 100 | Fatigue was resolved in 91% of participants versus placebo 15% by day 14 (p < 0.001) Improved mental and physical fatigue scores in the treatment group versus the control arm | No adverse events reported |
| Dehghan, Mente [128] Russia | To assess the efficacy and safety of probiotics for the treatment of hospitalized COVID-19 patients | Single center, open-label, randomized placebo-controlled trial Treatment: Probiotic formulation | Placebo n = 101 Treatment n = 99 | In patients who had diarrhea, it was resolved earlier in the treatment group versus the control group (p < 0.049) Hospital-acquired diarrhea occurred less frequently in the treatment group than the control group in patients who received a single antibiotic (p < 0.023), but not in those who had more than one antibiotic administered | Bacillus coagulans LBSC (DSM 17654), Bacillus subtilis PLSSC (ATCC SD 7280), and Bacillus clausii 088 A E (MCC 0538). |
| Zhang, Han [129] China | To retrospectively assess the efficacy of probiotic treatment in COVID-19 patients | Open label propensity-score matched retrospective cohort Jan – Apr 2020 Treatment: Probiotic formulation in conjunction with SOC SOC n = 179 | Reduced time to clinical improvement in treatment group (p = 0.022) Reduced hospital stay length in treatment group (p = 0.009) Shorter time to viral RNA clearance in throat swabs of treatment group (p < 0.001) No significant changes in blood counts, D-dimer, inflammatory biomarkers, liver enzymes, CD4+ or CD8+ T cell counts. | Lacticaseibacillus rhamnosusPDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longumsubsp. longum PDV 2301 |
| Li, Cheng [130] China | To retrospectively assess the efficacy of probiotic treatment of severe COVID-19 patients | Single-center retrospective cohort study Feb 2020 Treatment: Probiotic formulation in conjunction with SOC Mean treatment duration 12.9 days | Moderately reduced number of in-patient days in the treatment group (p < 0.001) Shorter time to viral RNA clearance in throat swabs of treatment group (p < 0.001) Probiotic groups had longer duration of antibiotic treatment (p < 0.001) and No significant difference of mortality and non-significant changes in CD4+ or CD8+ T cells and inflammatory markers reported | Oral Bifidobacterium infantis, Lactobacillus acidophilus, Dung enterococcus, and Bacillus cereus or Oral Bifidobacterium longum, Lactobacillus bulgaricus, and Streptococcus thermophilus or Oral Enterococcus faecium and Bacillus subtilis |

**Abbreviations:** ICU – Intensive care unit; SOC – Standard of care.
Table 2
A summary of some of the randomized controlled trials registered in ClinicalTrials.gov underway or recruiting that are investigating the application of probiotics for the prevention and/or treatment of COVID-19.

| Clinical Trial Identifier | Date Posted | Study Title                                                                 | Location                        | Study Design            | Intervention                                                                 | Outcomes Measured                                                                                     | Status          |
|---------------------------|-------------|------------------------------------------------------------------------------|---------------------------------|------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-----------------|
| NCT04366180              | 28-Apr-20   | Evaluation of the probiotic *Lactobacillus coryniformis* K8 on COVID-19 prevention in healthcare workers | Granada, Spain                  | Randomized parallel assignment | *Lactobacillus coryniformis* K8                                              | Incidence of infection by PCR or antigen test                                                         | Completed       |
| NCT04390477              | 15-May-20   | Study to evaluate the effect of a probiotic in COVID-19                       | Alicante, Spain                 | Randomized parallel assignment | Not disclosed                                                               | Percentage of patients admitted to ICU                                                               | Completed       |
| NCT04399252              | 22-May-20   | Effect of *Lactobacillus* on the microbiome of household contacts exposed to COVID-19 | North Carolina, United States   | Randomized parallel assignment | *Lactobacillus rhamnosus* GG                                                 | Incidence of COVID symptoms during the study period                                                   | Completed       |
| NCT04517422              | 18-Aug-20   | Efficacy of *L. plantarum* and *P. acidilactici* in adults with SARS-CoV-2 and COVID-19 | Mexico City, Mexico             | Randomized parallel assignment | *Lactobacillus plantarum* 30,292,7484 & 7485, & *Pediococcus acidilactici* | Severity progression, ICU duration & mortality ratio                                                 | Completed       |
| NCT04621071              | 9-Nov-20    | Efficacy of probiotics in reducing duration and symptoms of COVID-19 (PROVID-19) | Quebec, Canada                  | Randomized parallel assignment | Not disclosed                                                               | Duration before symptoms disappear                                                                  | Completed       |
| NCT04666116              | 14-Dec-20   | Changes in viral load in COVID-19 after probiotics                           | Valencia, Spain                 | Randomized parallel assignment | *Bifidobacterium longum*, *Bifidobacterium animalis subsp. lactis* and *Lactobacillus rhamnosus* | Impact on viral load in COVID-19 infected patients                                                   | Recruiting      |
| NCT04730284              | 29-Jan-21   | Evaluation of a symbiotic formula in patient with COVID-19                   | Hong Kong                       | Single group assignment      | Not disclosed                                                               | Changes in the gut microbiome measured at week 5                                                      | Recruiting      |
| NCT04734886              | 2-Feb-21    | The effect of probiotic supplementation on SARS-CoV-2 antibody response after COVID-19 | Sweden                          | Randomized parallel assignment | *Lactobacillus reuteri*                                                      | Specific antibodies in serum associated with SARS-CoV-2                                             | Completed       |
| NCT04756466              | 16-Feb-21   | Effect of the consumption of a *Lactobacillus* strain on the incidence of COVID-19 in the elderly | La Coruña, Spain                | Randomized parallel assignment | *Lactobacillus*                                                             | Incidence of infection by PCR or antigen test                                                         | Active, not recruiting |
| NCT04854941              | 22-Apr-21   | Efficacy of probiotics in the treatment of hospitalized patients with novel coronavirus infection | Moscow, Russia                  | Randomized parallel assignment | *Lactobacillus rhamnosus*, *Bifidobacterium bifidum*, *Bifidobacterium longum* | Mortality of patients during hospitalization                                                          | Completed       |
| NCT04877704              | 7-May-21    | Symprove (probiotic) as an add-on to COVID-19 management                     | London, United Kingdom          | Randomized single group assignment | Multi -Strain Probiotic (Symprove)                                           | Length of hospital stay                                                                               | Not yet recruiting |
| NCT04884776              | 13-May-21   | Modulation of gut microbiota to enhance health and immunity                  | Hong Kong                       | Randomized parallel assignment | Probiotics blend (3 Bifidobacteria)                                          | Percentage of patients achieving restoration of gut dysbiosis                                       | Recruiting      |
| NCT04907877              | 1-Jun-21    | Bifido- and *Lactobacilli* in symptomatic adult COVID-19 outpatients (ProCOVID) | Warsaw, Poland                  | Randomized parallel assignment | Mixture of bifido- and lactobacteria                                         | Global symptom score                                                                                 | Not yet recruiting |
| NCT04937556              | 24-Jun-21   | Evaluation of a probiotic supplementation in the immune response of participants with COVID-19 (coronavirus disease); (PROVID) | Madrid, Spain                   | Randomized parallel assignment | *Lactobacillus salivarius*                                                   | Concentration of specific antibodies related to SARS-CoV-2 virus                                    | Recruiting      |
| NCT04979065              | 27-Jul-21   | Nutrition, immunity, and COVID-19 in obese people (NICO)                     | Jakarta, Indonesia              | Phase 1: Cross-sectional Phase 2: Double-blind, randomized, placebo-controlled trial with two arms of intervention | Probiotics (Strain not disclosed) + Vitamin D, Zonulin & Vit D level, gut microbiome, inflammation markers, body mass index (BMI) | Not yet recruiting |

(continued on next page)
reduced hospital stay length ($p = 0.009$), and shorter time to RNA clearance measured via throat swabs ($p < 0.001$) in the treatment group. In accordance with these findings, Li, Cheng (130) reported a moderate reduction of in-patients days ($p < 0.001$) and shorter time to viral RNA clearance in throat swabs ($p < 0.001$) in COVID-19 patients receiving various probiotic formulations ($n = 123$) versus SOC ($n = 188$) in another retrospective study. In a preprint, Rathi, Jadhav [127] also reported improvements in patients receiving probiotics and an enzyme supplement. Indeed, 91/100 COVID-19 patients that received a probiotic (Bacillus coagulans, Bacillus subtilis, and Bacillus clausii) reported less physical and mental fatigue versus 15/100 placebo patients by day 14 of treatment ($p < 0.001$). However, it is not known whether these effects are a result of the probiotic or enzyme treatment or a combination of both. These studies together indicate that there may be a modest benefit of probiotic supplementation on time to patient recovery. However, blinded, randomized, placebo-controlled clinical trials are required to confirm these findings. In another trial that have been published (Table 1) [131], gastrointestinal symptoms appeared to improve ($p < 0.049$) and less frequent hospital-acquired diarrhea occurred ($p < 0.023$) in COVID-19 patients that received a probiotic ($n = 99$) versus those that received a placebo ($n = 101$) in a randomized, placebo-controlled trial. However, the aforementioned study by Li, Cheng (130) found that those who had received a probiotic (albeit a different formulation) required a longer duration of antibiotic treatment to recover from diarrhea.

![Fig. 1.](image)

**Table 2 (continued)**

| Clinical Trial Identifier | Date Posted | Study Title | Location | Study Design | Intervention | Outcomes Measured | Status |
|---------------------------|-------------|-------------|----------|--------------|---------------|-------------------|--------|
| NCT05043376               | 14-Sep-21   | Study to investigate the treatment benefits of probiotic Streptococcus salivarius K12 for mild-to-moderate COVID-19 | Lahore, Pakistan | Randomized parallel assignment | Streptococcus Salivarius K12 | Patients with clinical improvements | Recruiting |
| NCT05080244               | 15-Oct-21   | WHO COVID-19 - evaluation of the efficacy of probiotics to reduce the occurrence of long COVID (PROVID-LD) | Quebec, Canada | Randomized parallel assignment | Not disclosed | COVID-19 symptoms, anxiety, functioning difficulties 90 days after the diagnosis | Recruiting |

Fig. 1. Bacteriocins such as plantaricin secreted by probiotic bacteria such as L. plantarum are predicted to be involved in inhibiting SARS-CoV-2 entry and replication. Molecular docking studies have projected that the plantaricin construct may obstruct the entry of the virus by targeting S protein or bind to the RNA-dependent RNA polymerases (RdRP) thereby impeding transcription of the genome.
5. Proposed mechanisms of action for probiotics in COVID-19

The studies discussed in this review indicate that there may be some benefits to probiotic administration but considering the current pandemic and the progress made on existing therapeutics [132] it is not known whether probiotics may impact patient outcomes. Despite the many potential mechanisms already discussed in this review, a clearer understanding of the implicated mechanisms of action of probiotics to alleviate COVID-19 symptoms are not yet studied in detail. However, a few published studies speculate and/or provide insight into the role of bioactive compounds produced by probiotic bacteria in COVID-19 management as depicted in Fig. 1. Apart from the mechanisms of anti-inflammatory action, immune modulation, and modulation of the microbiome previously discussed, probiotics may also inhibit the binding of SARS-CoV-2 to its receptor via bacteriocins. Bacteriocins are antimicrobial peptides or proteins synthesized by Gram-positive and Gram-negative bacteria commonly found in fermented foods and currently under investigation as potential food additives and antimicrobial therapeutic agents [133,134]. An in-silico study by Anwar et al. [135] used protein modeling to propose a mechanism of action for metabolic products of Lactobacillus plantarum in COVID-19 management. Using a molecular dynamics simulation model, the study suggested that Plantaricin (Pln) W, D, and JLA-9- compounds inhibit the entry of SARS-CoV-2 by blocking ACE2 receptors and virus transcription by targeting the S protein and blocking RNA polymerase (RdRp). Additionally, in vitro study by Rather, Choi (136) showed reduction in SARS CoV-2 viral titers post treatment with cell free supernatant from L. plantarum- Probio-88. Furthermore, molecular docking by Rather et al. predicted that PlnE and PlnF from L. plantarum could inhibit the SARS-CoV-2 replication by binding at either ssRNA or ATP binding sites of helicase. Molecular docking studies have also indicated the potential of pediocin PA-1, salivaricin P, and salivaricin B to bind with the SARS-CoV-2 spike protein receptor-binding domain, thereby inhibiting viral entry into host cells [137]. Considering endogenous microbial peptides such as cathelicidin are under investigation for their effects on SARS-CoV-2 infection [82], further studies of administration of antimicrobial peptides or probiotics are warranted.

6. Future perspectives on probiotics and COVID-19

Moving forward, there are several factors trialists should consider in relation to the gut microbiome, probiotics, COVID-19. For instance, it is important to consider the intervention duration while studying the effects of dietary strategies, treatments or interventions on the gut microbiota because the gut microbiota responds rapidly to short-term dietary alterations, however, long-term dietary interventions may only maintain microbiota changes if the intervention becomes habitual, due to the fact that ceasing the intervention can cause the microbiota composition to revert back to pre-intervention composition [138]. This concept explains the “responder/non-responder” phenomenon, which is based on the changes of an individual’s gut microbiota in response to prebiotic interventions [139,140]. The utility of prebiotics and synbiotics has also largely been neglected. Prebiotics are fibers including various oligosaccharides provided by foods or supplements that promote the growth or activity of healthy microorganisms in the gut. On the other hand, synbiotics are a mixture of both probiotics and prebiotics that can be ingested via foods or supplements with intended health benefits [141]. To date, the beneficial effects of prebiotic, probiotic, and synbiotics on the host’s antiviral response have mostly focused on the intestinal tract with limited evidence on their ability to modulate responses in distant respiratory mucosal sites.

Another notable issue is that the ongoing clinical trials have used bacterial formulations capable of eliciting specific anti-inflammatory and antiviral activities [142,143]. However, studies have shown that not all probiotics are created equal, nor do they elicit the same immune benefits. For example, L. plantarum CRL1506 stimulates antiviral intestinal immunity, however, is incapable of modulating respiratory antiviral immune response [144,145]. Therefore, results between trials are not always directly transferable or interpretable to other bacterial preparations and there may be considerable heterogeneity between trial outcomes. Depending on the delivery mechanisms, which is generally oral consumption, some probiotics may be prone to degradation by the digestive system, hence why novel methods of probiotic delivery are being assessed [146]. Indeed, next-generation probiotics, which are probiotic formulations more akin to pharmaceutical-grade supplements, are also being investigated for various conditions, but have yet to be fully explored for COVID-19 [86,146].

Additionally, while inferring the results of clinical trials (Table 1, Table 2) it is important to be aware of confounding factors such as various age groups with different immune system statuses, the season of the year, doses of probiotics, nutritional status, other supplements being consumed, etc. Therefore, a more targeted approach may be warranted, whereby a patients gut microbiota profile is sequenced at a bacterial strain level to fully address the role of the microbiota and their interactions between diet and extrinsic stressors against SARS-CoV-2 infection. This level of diagnostic capacity could potentially lead to personalized treatments or formulations of probiotics or next-generation probiotics in the future.

An important question is if these probiotics, probiotics, and synbiotics can be used for preventive or therapeutic interventions? None of the published studies have reported using these immunobiotics for the management of COVID-19. Considering the fact that people with co-morbidities are at higher risk of worse outcomes post SARS-CoV-2 exposure, these bacterial formulations should be considered to strengthen the immune response of healthy and at-risk populations rather than a therapeutic measure. People with comorbidities, old age, nightshift, and jetlag are more susceptible to disease progression owing to disrupted circadian rhythms and vice-versa [147–149]. Recent studies have shown that host circadian rhythms influence the outcomes of respiratory infections [150,151]. One cannot ignore a tripartite crosstalk between circadian rhythm, commensals and viral infections while considering microbial formulations as a supplement for COVID-19 management [152], especially since patients in intensive care units suffer from circadian rest/activity misalignment [153], which may affect the microbiome and lead to severe disease outcomes.

Probiotics are not a panacea for the treatment of COVID-19, but their potential modulation of the gut microbiome may beneficially or negatively affect the efficacy and bioavailability of some drugs, including those that were on trial for treatment of COVID-19. It is important to consider the role of the microbiome and its interactions with drug metabolism and pharmacokinetics [154,155]. Some drugs are metabolized by the microbiome and therefore their efficacy and bioavailability may be affected [156]. Some drugs negatively affect the microbiome [157]. For example, tocilizumab, an anti-IL-6 monoclonal antibody used to treat ARDS in COVID-19 that may affect the microbiome. Individuals with diverticular disease, a disease known to alter the gut microbiome, are at higher risk of lower intestinal perforation when medicated with tocilizumab [158]. Indeed, IL-6 deficient mice also have thinning of the mucus layers and impaired gut-epithelial barrier function [159]. This indicates that COVID-19 patients treated with tocilizumab may impair gut-epithelial barrier function via IL-6 depletion. Therefore, these patients may be candidates to receive probiotic treatments to
ameliorate dysbiosis induced by both COVID-19 and resulting treatments. In fact, it is largely unknown what effects other medications targeting COVID-19 may have on microbiota, thus further research is required.

The efficacy and the safety of probiotics has been contentious in the literature. For example, a case report on an immunocompromised patient showed development of fungemia as a result of treatment of antibiotic-associated pseudomembranous colitis with the probiotic *Saccharomyces cerevisiae* var. *Bouardi* [160]. Another report presented a clinically significant bacteremia in immunocompromised patients who received *Bacillus clausii* [161]. A clinical study conducted at Boston Hospital showed alarming results of developing *Lactobacillus* bacteremia in ICU patients who received *Lactobacillus rhamnosus* strain GG (LGG) probiotics [162]. Moreover, Kothari et al. have written an exhaustive review on deleterious effects of administration of probiotics that were not only limited to localized and opportunistic infections but also resulted in sepsis, ischemia, infective endocarditis, and horizontal transfer of antibiotic resistant genes [163]. At the time of writing, there is no direct evidence that probiotics or their metabolites or bioactive compounds attenuate the complex symptoms related to COVID-19.

Probiotics also come in various compositions and so it is likely that multiple mechanisms contribute to some of the observed benefits of their administration against respiratory infections and COVID-19. However, determining the most effective composition and concentration will be important if probiotics are to be used in COVID-19 treatment. Formulations may also need to be adjusted depending on the symptoms. Indeed, a formulation that may be beneficial for one patient could be detrimental to another. Therefore, considerably more research is required.

Among the limited studies published to date, there appears to be some promising but mixed results for the use of probiotics in hospitalized COVID-19 patients. Indeed, many of the trials that have been registered (Table 2) are further investigating the potential therapeutic benefits of co-administering probiotics with SOC. Until these findings have been published, it is not possible to provide evidence-based recommendations for the administration of probiotics to patients and therefore, we conclude that probiotics have not yet been shown to be substantially effective against COVID-19 to warrant inclusion in COVID-19 treatment plans. However, complementary use of probiotics as an adjuvant treatment may be used cautiously for the enhancement of antiviral defenses and prevention of secondary microbial infections as was previously proposed by the Chinese health authorities [164]. Further research is required to discern the role of the microbiome in the gut-lung axis and the role of probiotics in the prevention and treatment of SARS-CoV-2 and COVID-19 and the modulation of the gut and lung microbiomes.

**Author contributions**

Conceptualization, R.L.; writing—original draft preparation, S.B., A.N., and R.L.; writing—review and editing, S.B., A.B., and R.L.; Visualization, A.N; project administration and supervision, R.L. All authors have read and agreed to the published version of the manuscript.

**Declaration of Competing Interest**

The authors have no conflicts of interest to declare. This study did not receive funding.

**Acknowledgments**

A.N. and R.L. would like to thank the Children’s Hospital of Philadelphia, the Institute for Translational Medicine and Therapeutics, and the Perelman School of Medicine for their continued support. Figure created using Biorender.

**References**

[1] John Hopkins University. John Hopkins University & Medicine: Coronavirus Resource Center. 2020. Available from: https://coronavirus.jhu.edu/map.html.

[2] Kang E-J, Kim SY, Hwang I-H, Ji Y-J. The effect of probiotics on prevention of common cold: a meta-analysis of randomized controlled trial studies. Korean J Fam Med 2013;34(1):2—10.

[3] Kanauchi O, Andoh A, AbuBakar S, Yamamoto N. Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems. Curr Pharmaceut Des 2018;24(6):710—7.

[4] Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11(8):506—14.

[5] Reid G. Probiotics: definition, scope and mechanisms of action. Best Pract Res Clin Gastroenterol 2016;30(1):17—25.

[6] Rijker G, de Vos WM, Brummer RJ, Morelli L, Cordier G, Marteau P. Health benefits and health claims of probiotics: bridging science and marketing. Br J Nutr 2011;106(9):1291—6.

[7] Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, et al. An update on the use and investigation of probiotics in health and disease. Gut 2013;62(5):787—96.

[8] Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res 2017;61(1):1600240.

[9] NIH. PubMed 2022 [Available from]: https://pubmed.ncbi.nlm.nih.gov.

[10] Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science 2012;336(6086):1262—7.

[11] Ursell LR, Metcalf Jr JF, Parfey LW, Knight R. Defining the human microbiome. Nutr Rev 2012;70(Suppl 1):S38—44.

[12] Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017;474(11):1823—36.

[13] Hoffmann AR, Proctor LM, Surette MG, Suchodolski JS. The microbiome—the trillions of microorganisms that maintain health and cause disease in humans and companion animals. Vet Pathol 2016;53(1):10—21.

[14] Klingelhofer L, Reichmann H. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nat Rev Neurol 2015;11(11):625—36.

[15] Cryan JF, O’Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The microbiota-gut-brain Axis. Physiol Rev 2019;99(4):1877—2013.

[16] Conte L, Toraldo DM. Targeting the gut–lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis 2020;14:1753466620937170.

[17] Aktas B, Atilim B. Gut-lung axis and dysbiosis in COVID-19. Turk J Biol 2020;44(3):265—72.

[18] Dhar D, Mohanty A. Gut microbiota and Covid-19: possible link and implications. Virus Res 2020;285:1908018.

[19] Easa A, Reve J, Viefen C, Carlo E, Beaufils F, Wierse G, Gaery R, et al. The gut-lung Axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalk. Front Cell Infect Microbiol 2020:10(9).

[20] Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The role of lung and gut microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis 2020;14:1753466620937170.

[21] Aktaş B, Atilim B. Gut-lung axis and dysbiosis in COVID-19. Turk J Biol 2020;44(3):265—72.

[22] Dharia D, Mohanty A. Gut microbiota and Covid-19: possible link and implications. Virus Res 2020;285:1908018.

[23] Easa A, Reve J, Viefen C, Carlo E, Beaufils F, Wierse G, Gaery R, et al. The gut-lung Axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalk. Front Cell Infect Microbiol 2020:10(9).

[24] Xiao J, Chu M, Zhong F, Tan X, Tang G, Mai J, et al. Diagnostic symptoms of COVID-19 and expression of ACE2 in digestive tract organs. Cell Death Dis 2020;11:676.

[25] Xu J, Chu M, Zhong F, Tan X, Tang G, Mai J, et al. Diagnostic symptoms of COVID-19 and expression of ACE2 in digestive tract organs. Cell Death Dis 2020;11:676.

[26] Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut 2020;69(6):1141—3.

[27] Kang KS, Hung IFN, Chan PPy, Lung KC, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology 2020;159(1):81—95.

[28] Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang J, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 2020;69(6):997—1001.

[29] Pizzurro A, Brim H, Askhotorab H. Gastrointestinal manifestations and SARS-CoV-2 infection. Curr Opin Pharmacol 2021;61:114—9.
[30] Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Transl Res 2020;226:57–69.
[31] Richardson DP, MacIntyre NA. Nutritional status of micronutrients as a possible and modifiable risk factor for COVID-19: A UK perspective. Br J Nutr 2021;125(6):678–84.
[32] Kurilshikov A, Medina-Gomez C, Bicaigalupi R, Radjabzadeh D, Wang J, Deaton C, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet 2021;53(2):156–65.
[33] Allen JM, Mailing LJ, Niemmo GM, Moore R, Cook MD, White BA, et al. Exploring alters gut microbiota composition and function in lean and obese humans. Med Sci Sports Exerc 2018;50(4):747–57.
[34] Yamamoto S, Saito M, Tamura A, Prasivudas D, Mizutani T, Yotsuyanagi H. The human microbiome and COVID-19: a systematic review. PLoS One 2021;16(6):e0253293.
[35] Spagnolello O, Pinacchio C, Santinelli L, Vassalini P, Innocenti GP, De Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in COVID-19 disease. Microb Ecol Health Dis 2015;26:26191.
[36] Eguchi K, Fujitani N, Nakagawa H, Miyazaki T. Prevention of respiratory tract fibrosis in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials. New Microb and Novel Pathog 2021;40:100837.
[37] Eguchi K, Fujitani N, Nakagawa H, Miyazaki T. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Sci Rep 2019;9(1):4812.
[38] Tomosada Y, Chiba E, Zelaya H, Takahashi T, Tsukida K, Kitazawa H, et al. Orally administered Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly(I:C). BMC Immunol 2012;13(1):53.
[39] Villenca J, Chiba E, Tomosada Y, Salva S, Marranzino G, Kitazawa H, et al. Orally administered Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly(I:C). BMC Immunol 2012;13(1):53.
[40] Singh RK, Chang H-W, Yan D, Lee KM, Ucmak D, Wong K, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med 2017;15(1):73.
[41] Brahma S, Martiniez I, Walter J, Clarke J, Gonzalez T, Menon R, et al. Impact of dietary pattern of the feline donor on in vitro fermentation properties of whole grains and brans. J Funct Foods 2017;29:281–9.
[42] Jardou M, Lawson R. Supportive therapy during COVID-19: the proposed mechanism of short-chain fatty acids to prevent cytokine storm and multi-organ failure. Med Hypotheses 2021;154:110661.
[43] Li J, Li Richards EM, Handberg EM, Peippe CJ, Raizada MK. Butyrate regulates COVID-19–relevant genes in gut epithelial organoids from normothemic rats. Hypertension 2021;77(2):212–17.
[44] Pascoal LB, Rodrigues PB, Vieira AT, Gomes ABdSP, Toledo-Teixeira DA, Fagundes CT, Amaral FA, Nicoli JR, et al. Effects of dietary intervention of short-chain fatty acid and L-isoleucine biosynthesis in gut microbiome in rats. Hypertension 2021;77(2):e13-1.
[45] Alwarawrah Y, Kiernan K, MacIver NJ. Changes in nutritional status impact the lung and the role of nutrition in potential mitigation. Nutrients 2020;12(5):1466.
[46] Thang NTH, Long NP, Hue TTM, Hung LP, Trung TD, Dinh DN, et al. Association of changes in nutritional status and dengue infection: a comprehensive review. Front Immunol 2019;10(1551).
[47] Deschaux-Tanguy M, Saurat B, Bourhis L, Arnaud N, Druennse-Feccolio E, Eseddik Y, et al. Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-Sante cohort. BMC Med 2021;19(1):240.
[48] Zebatukis I, Lordan R, Norton C, Tougas P. COVID-19: the inflammation link and the role of nutrition in potential mitigation. Nutrients 2020;12(5):1466.
[49] Lordan R. Notable developments for vitamin D amid the COVID-19 pandemic, but caution warranted overall: a narrative review. Nutrients 2021;13(3):740.
[50] O’Connor EM. The role of gut microbiota in nutritional status. Curr Opin Clin Nutr Metab Care 2013;16(5):509–16.
[51] Golonka RM, Xiao X, Abokor AA, Joe B, Vijay-Kumar M. Altered nutrient status regresses host inflammation and metabolic health via gut microbiota. J Nutr Biochem 2020;80:108360.
[52] Daost L, Pilon C, Marette A. Perspective: nutritional strategies targeting the gut microbiome to mitigate COVID-19 outcomes. Adv Nutr 2021;12(4):806–90.
[53] Lordan R, Rando HM , COVID-19 review Consortium, Greene CS. Dietary supplements and nutraceuticals under investigation for COVID-19 prevention and treatment. mSystems 2021;6(3):e00122. 21.
[54] Coward WA, Bates JS, Shirali RH, Stratton RJ. A review of nutrition support guidelines for individuals with or recovering from COVID-19 in the community. Nutrients 2020;12(11):3230.
Bradley ES, Gaibani P, Castagnetti A, Liberatore A, Bartolotti M, Viale P, et al. Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp. Infect Dis Clin Pract 2022;30:217–23.

Gaibani P, Viciani E, Bartolotti M, Lewis RE, Tonetti T, Lombardo D, et al. The lower respiratory tract microbiome of critically ill COVID-19 patients. Microbandlef 2021;31(4):1710–6.

Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J, et al. Six-month follow-up of gut microbiota richness in COVID-19 patients. Gut 2022;71(1):222–5.

Huisingh K, Pali-Scholz I, Roth-Walter F, Jensen-Jarolim E. Dysbiosis of the gut and lung microbiome has a role in asthma. Semin Immunopathol 2020;42(1):75–93.

Willis KA, Stewart JD, Ambalavanan N. Recent advances in understanding the ecology of the lung microbiota and deciphering the gut-lung axis. Am J Phys Lung 2020;319(4):1710–6.

Martinez JE, Vargas A, Perez-Sanchez T, Encio J, Cabello-Olmo M, Barajas M. Human microbiota network: unveiling potential crosstalk between different microbiota ecosystems and their role in health and disease. Nutrients 2021;13(9):2905.

Zhong H, Ai J-W, Yang W, Zhou X, He F, Xie S, et al. Metatranscriptomic characterization of coronavirus disease 2019 identified a host transcriptional classifier associated with immune signaling. Clin Infect Dis 2020;73(3):376–85.

Ai J-W, Zhang H-C, Xu T, Wu J, Zhu M, Yu Y-Q, et al. Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China. Front Microbiol 2020;11:23026257.

Budding A, Siersweda E, Wintersmann B, Bos M. An age-dependent pharyngeal microbiota signature associated with SARS-CoV-2 infection. 2020. Available at: SSRN 3582780.

Gutierrez MV, van Tilburg Bernardes E, Changirwa D, McDonald B, Arrieta M-C. “Molding” immunity— modulation of mucosal and systemic immunity by the intestinal mycobiome in health and disease. Mucosal Immunol 2022;15:573–83.

van Tilburg Bernardes E, Pettersen VK, Gutierrez MW, Laforest-Lapointe J, Jendziojwsky NG, Cavin JB, et al. Intestinal fungi are causally implicated in microbiome assembly and immune development in mice. Nat Commun 2020;11(1):2577.

Trotsikis A, Zha BS, Byrne A, DeCoevo V, Racaillete E, Levan S, et al. Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19. medRxiv 2021. 2021.03.23.21253487.

Bradley ES, Zeamer AL, Bucci V, Cinclastro L, McDonald B, Arrieta M-C. “Molding” immunity—modulation of mucosal and systemic immunity by the intestinal mycobiome in health and disease. Mucosal Immunol 2022;15:573–83.

Zhang H, Zhang L, Han H, Li X, Chen C, Xie X, Su G, et al. Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19. Therap Adv Gastroenterol 2021;14:17562848211035670.

Li Q, Cheng F, Xu Q, Yu Y, Cai X, Zeng F, et al. The role of probiotics in coronavirus disease-19 infection in Wuhan: a retrospective study of 311 severe patients. Int Immunopharmacol 2021;95:107531.

Ivashkin V, Fominy V, Moiseev S, Brovko M, Maslennikov R, Ulyanin A, et al. Effectiveness of a probiotic consisting of lactobacillus rhamnosus RDS 1705, Bifidobacterium bifidum RDS 2103, and Bifidobacterium longum subsp. longum RDS 2301 in the treatment of critically ill patients with COVID-19. Probiotics and Antimicrobial Proteins 2021. https://doi.org/10.1007/s12602-021-09858-5.

Rando HM, Weilnauener N, Ghosh S, Lee AJ, Dattoli AA, Hu F, et al. Identification and development of therapeutics for COVID-19. mSystems 2021;6(6):

Soltani S, Hammami R, Cotter PD, Rebuffat S, Said LB, Gaudreau H, et al. Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulatory considerations. FEMS (Fed Eur Microbiol Soc) Microbiol Rev 2020;45(1).

Chopra AS, Lordan R, Horba Zuo T, Liu Q, Zhang F, Lui GC-Y, Tso EY, Yeoh YK, et al. Effects of Lactobacillus casei paracasei C8 CECT75711 on the immune response to influenza vaccination and the assessment of common respiratory symptoms in elderly subjects: a randomized controlled trial. Eur J Nutr 2021;60(3):819–30.

Shahbazi R, Yasavoli-Sharahi H, Alsadi N, Ismail N, Matar C. Probiotics in treatment of viral respiratory infections and neuroinflammatory disorders. Molecules 2020;25(21):4891.

Oliveira PW, Marchetti MC. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nature Microbiol 2017;2(5):17057.

Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Adv Nutr 2019;10(suppl_1):S49–S61.

Lei W-T, Shi P-C, Liu S-J, Lin C-Y, Yeh T-L. Effect of probiotics and prebiotics on immune response to influenza vaccination in adults: a systematic review and meta-analysis of randomized controlled trials. Nutrients 2019;7(11):1753.

Zhang L, Han H, Li X, Chen C, Xie X, Su G, et al. Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19. Therap Adv Gastroenterol 2021;14:17562848211035670.

Anwar F, Altayb HN, Al-Abbasi FA, Al-Malki AL, Kamal MA, Kumar V. Anti-inflammatory effects of probiotic metabolites on COVID-19. J Biomol Struct Dyn 2021;39(11):4175–84.

Erol I, Kotil SE, Fidan O, Yetimian AE, Durdagi S, Oztarli F. In Silico analysis of Bacteriocins from lactic acid bacteria against SARS-CoV-2, Probiotics and Antimicrobial Proteins 2021. https://doi.org/10.1007/s12602-021-09879-0.

Korpela K, Flint HJ, Johnstone AM, Lappi J, Poutanen K, Dewulf E, et al. Gut microbiota signatures predict host and microbiota responses to dietary interventions in obese individuals. PLoS One 2014;9(10):e111711.

Sonnenburg JL, Backdell F. Gut-microbiota interactions as moderators of human metabolism. Nature 2016;535(7610):56–64.

Swanson KS, Gibson GR, Hutkins R, Reimr RA, Reid G, Verbeke K, et al. The International Scientific Association for Probiotics and Prebiotics (SAPP)
consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol 2020;17(11):687–701.

[142] Tada A, Zelaya H, Cisa P, Salva S, Alvarez S, Kitazawa H, et al. Immunobiotic Lactobacillus strains reduce small intestinal injury induced by intraepithelial lymphocytes after Toll-like receptor 3 activation. Inflamm Res 2016;65(10):771–83.

[143] Albarracin L, Kohayashi H, Iida H, Sato N, Nochi T, Aso H, et al. Transcriptomic analysis of the innate antiviral immune response in porcine intestinal epithelial cells: influence of immunobiotic lactobacilli. Front Immunol 2017;8(57).

[144] Chiba E, Tomosada Y, Vizoso-Pinto MG, Salva S, Takahashi T, Tsukida K, et al. Immunobiotic Lactobacillus rhamnosus improves resistance of infant mice against respiratory syncytial virus infection. Int Immunopharm 2013;17(2):373–82.

[145] Zelaya H, Tsukida K, Chiba E, Marranzino G, Alvarez S, Kitazawa H, et al. Immunobiotic lactobacilli reduce viral-associated pulmonary damage through the modulation of inflammation-coagulation interactions. Int Immunopharm 2014;19(1):161–73.

[146] Gautier T, David-Le Gall S, Sweidan A, Tamanai-Shacoori Z, Jolivet-Gougeon A, Lor/C19 eal O, et al. Next-generation probiotics and their metabolites in COVID-19. Microorganisms 2021;9(5):941.

[147] Salehinejad MA, Azarkolah A, Ghanavati E, Nitsche MA. Circadian disturbances, sleep difficulties and the COVID-19 pandemic. Sleep Med 2021;91:246–52.

[148] Zhuang X, Tsukuda S, Wrensch F, Wing PAC, Schilling M, Harris JM, et al. The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. iScience 2021;24(10):103144.

[149] Kothari D, Patel S, Kim S-K. Probiotic supplements might not be universally-effective and safe: a review. Biomed Pharmacother 2019;111:537–47.

[150] Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis 2020;21(3):125–6.